BioCentury | Sep 28, 2018
Emerging Company Profile

Stopping chain swapping

By controlling how antibody chains pair, Elstar Therapeutics Inc.’s platform can produce multispecific antibodies at yields comparable to methods for manufacturing monospecific antibodies. The company develops multispecific antibodies with up to four functional domains that...
BC Week In Review | Feb 9, 2018
Clinical News

Affimed reports Phase Ib/IIa data of AFM13 for cutaneous lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from three evaluable patients with relapsed or refractory CD30-positive, cutaneous lymphoma in the first dose cohort of a Phase Ib/IIa trial showing that once-weekly 1.5 mg/kg IV AFM13 led to...
BC Week In Review | Feb 9, 2018
Clinical News

Affimed reports Phase Ib data of AFM13 plus Keytruda for Hodgkin's lymphoma

Affimed N.V. (NASDAQ:AFMD) reported data from nine evaluable patients with relapsed or refractory Hodgkin's lymphoma in a Phase Ib trial showing that 7 mg/kg IV AFM13 plus anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co....
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BC Week In Review | Oct 27, 2017
Clinical News

NantKwest begins Phase I of NK cell therapy for solid tumors

NantKwest Inc. (NASDAQ:NK) began the 2-part Phase I QUILT-3.028 trial of its haNK cell therapy to treat metastatic or locally advanced solid tumors. The first part of the 16-patient trial will evaluate weekly infusions of...
BC Innovations | Aug 29, 2017
Distillery Therapeutics


INDICATION: Thrombocytopenia Mouse studies suggest depleting NK cells or inhibiting NK cell activation could help treat fetal/neonatal alloimmune thrombocytopenia (FNAIT). In a mouse model of FNAIT, a tool antibody that depletes NK cells decreased uterine...
BC Extra | Aug 11, 2017
Preclinical News

Study links FNAIT miscarriages to NK cells

In a paper published in Nature Communications , a team including scientists from St. Michael's Hospital and University of Toronto showed that NK cell activation leads to placental dysfunction and miscarriages in fetal/neonatal alloimmune thrombocytopenia (FNAIT)....
BC Extra | Jun 12, 2017
Company News

Celgene gets options to Dragonfly's NK receptor antibodies

Dragonfly Therapeutics Inc. (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) began a five-year collaboration to discover, develop and commercialize candidates to treat hematologic malignancies based on Dragonfly’s TriNKET (Trispecific NK cell Engager Therapies) platform. Celgene will...
BioCentury | Mar 3, 2017
Emerging Company Profile

Dragonfly’s trinkets

Dragonfly Therapeutics Inc. is developing trispecific antibodies that direct endogenous NK cells toward tumor cells. By targeting two distinct activating receptors on NK cells, plus a tumor antigen, the antibodies could be more potent than...
BC Innovations | Feb 28, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers IgG antibodies with high affinity for FCGR3A could help predict the severity of dengue fever. Fifteen patients with dengue virus infection who developed dengue hemorrhagic fever or dengue shock syndrome had higher...
Items per page:
1 - 10 of 17